Post-Traumatic Stress Disorder (PTSD) Market to Showcase Significant Growth During the Forecast Period (2019-32) - Estimates DelveInsight | Key Companies - Freespira, Aptinyx (NYX-783), Jazz Pharma (JZP150), Aptinyx (NYX-783), Otsuka ((Rexulti (brexpipraz

As per DelveInsight's assessment, the Post-Traumatic Stress Disorder (PTSD) Market size was found to be USD 1,740.2 million in 2021, which is expected to rise during the study period (2019-2032). Some of the key factors, such as the increase in prevalence, the launch of emerging therapies, and increased initiatives to create public awareness and knowledge of the disease, are anticipated to drive market growth. The leading pharma and biotech giants working in the therapeutic market include Jazz Pharmaceuticals, Aptinyx, Otsuka Pharmaceutical, Bionomics Limited, and others.

DelveInsight's "Post-Traumatic Stress Disorder Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Post-Traumatic Stress Disorder Market Size and Share in the 7MM (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Post-Traumatic Stress Disorder market report covers emerging drugs, treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Post-Traumatic Stress Disorder (PTSD): An Overview
Post-traumatic stress disorder (PTSD) has been described as "the complex somatic, cognitive, affective, and behavioral effects of psychological trauma." It is characterized by intrusive thoughts, nightmares, and flashbacks of past traumatic events, avoidance of reminders of trauma, hypervigilance, and sleep disturbance, all of which lead to considerable social, occupational, and interpersonal dysfunction.

According to the American Psychiatric Association, PTSD affects approximately 3.5 percent of US adults annually, and an estimated one in 11 people will be diagnosed with PTSD in their lifetime. Women are twice as likely as men to have PTSD.

Post-Traumatic Stress Disorder (PTSD) Market Key Facts
The total market size of Post-Traumatic Stress Disorder (PTSD) in the United States was USD 1,549.9 million in 2021, which is expected to rise during the study period (2019-2032).
In EU5, the total market size of Post-Traumatic Stress Disorder (PTSD) was USD 163.4 million in 2021.
The prevalence population cases of PTSD was 13,538.4 thousand (K) cases in the 7MM in the year 2021, which might rise to reach 14,912.0 K cases by 2032 at a CAGR of 0.9%.
In the 7MM, the highest number of prevalent cases of PTSD was observed in the US.
In EU4 and the UK countries, the prevalent population cases of PTSD were 3,347.1 K cases in the year 2021, which is estimated to rise and reach 3,573.9 K cases by the year 2032 at a CAGR of 0.6%.
In the year 2021, the severity-specific cases of PTSD were 1,692.0 K cases for mild, 1,707.2 K cases for moderate, and 1,941.8 K cases for severe, respectively, in the 7MM.

Post-Traumatic Stress Disorder (PTSD) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Post-Traumatic Stress Disorder market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Post-Traumatic Stress Disorder market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How Post-Traumatic Stress Disorder Market will Grow by 2032:
https://www.delveinsight.com/report-store/post-traumatic-stress-disorder-ptsd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Post-Traumatic Stress Disorder (PTSD) Epidemiology
The epidemiology section covers detailed insights into the historical and current Post-Traumatic Stress Disorder patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Post-Traumatic Stress Disorder (PTSD) Epidemiology Segmented by -
Total Treated cases of PTSD in the 7MM (2019-2032)
Prevalence population of PTSD in the 7MM (2019-2032)
Diagnosed prevalent Cases of PTSD in the 7MM (2019-2032)
Severity-specific Cases of PTSD in the 7MM (2019-2032)
Gender-specific Cases of PTSD in the 7MM (2019-2032)
Age-specific Cases of PTSD in the 7MM (2019-2032)

Post-Traumatic Stress Disorder (PTSD) Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Post-Traumatic Stress Disorder market or expected to be launched during the study period. The analysis covers Post-Traumatic Stress Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Post-Traumatic Stress Disorder Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities:
https://www.delveinsight.com/report-store/post-traumatic-stress-disorder-ptsd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Major Clinical, Commercial and Regulatory Developments in the Post-Traumatic Stress Disorder (PTSD) Therapeutics Market
On November 17, 2022, MAPS Public Benefit Corporation ("MAPS PBC") announced the final participant visit had been completed in MAPP2, a multi-site Phase 3 study of MDMA-assisted therapy ("MDMA-AT") for post-traumatic stress disorder ("PTSD").
In August 2021, The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, announced that it had entered an agreement with Aché Laboratórios Farmacêuticos S.A. (Aché), a leader in the Latin American pharmaceutical market, to co-develop a therapy with the potential to treat general anxiety disorder (GAD) and post-traumatic stress disorder (PTSD).
In February 2021, Bionomics Limited announced that it had entered into a Memorandum of Understanding with EmpathBio Inc. Under the Memorandum of Understanding, Bionomics and EmpathBio propose to collectively explore a combination drug treatment regimen with Bionomics' BNC210 and EmpathBio's 3,4-Methylenedioxymethamphetamine (MDMA) derivative EMP-01.

Post-Traumatic Stress Disorder (PTSD) Therapeutics Assessment
The treatment of patients with PTSD relies on a multidimensional approach. Treatment options include patient education, social support, and anxiety management through psychotherapy and psychopharmacology intervention. Patient education and social support are important initial interventions to engage the patient and mitigate the impact of the traumatic event.

PTSD is a mental health condition that's triggered by a terrifying event - either experiencing it or witnessing it, and therefore, the emerging landscape of this condition is robust. There are several major pharma and biotech giants developing therapies for Post-traumatic stress disorders. The projected introduction of emerging therapies is anticipated to transform the treatment market space in the coming years. Currently, Otsuka Pharmaceutical Development & Commercialization has its Post-traumatic stress disorders drug candidates in the most advanced stage of clinical development among the major key players operating in the market.

The Leading Companies in the Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Include:
Alto Neuroscience
Aptinyx
AstraZeneca
Bionomics Limited
Boehringer Ingelheim
GlaxoSmithKline
H. Lundbeck A/S
Jazz Pharmaceuticals
Nobilis Therapeutics
Otsuka Pharmaceutical Development & Commercialization, Inc.
Pfizer
Remedy
Sage Therapeutics
Tonix Pharmaceuticals, Inc.
Yale University
And Many Others

Post-Traumatic Stress Disorder (PTSD) Therapeutics Drugs Covered and Analyzed in the Report Include:
Lu AG06466: H. Lundbeck A/S
NBTX-001 Xenon Inhaler: Nobilis Therapeutics
JZP150: Jazz Pharmaceuticals
NYX-783: Aptinyx
BNC210: Bionomics Limited
Rexulti (brexpiprazole) and Zoloft (sertraline) combination: Otsuka Pharmaceutical Development & Commercialization, Inc.
And Many More

Learn More About the Emerging Therapies & Key Companies in the Post-Traumatic Stress Disorder Therapeutics Market:
https://www.delveinsight.com/sample-request/post-traumatic-stress-disorder-ptsd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Post-Traumatic Stress Disorder Competitive Intelligence Analysis
4. Post-Traumatic Stress Disorder Market Overview at a Glance
5. Post-Traumatic Stress Disorder Background and Overview
6. Post-Traumatic Stress Disorder Patient Journey
7. Post-Traumatic Stress Disorder Epidemiology and Patient Population
8. Post-Traumatic Stress Disorder Treatment Algorithm, Current Treatment, and Medical Practices
9. Post-Traumatic Stress Disorder Unmet Needs
10. Key Endpoints of Post-Traumatic Stress Disorder Treatment
11. Post-Traumatic Stress Disorder Marketed Products
12. Post-Traumatic Stress Disorder Emerging Therapies
13. Post-Traumatic Stress Disorder Seven Major Market Analysis
14. Attribute Analysis
15. Post-Traumatic Stress Disorder Market Outlook (7 major markets)
16. Post-Traumatic Stress Disorder Access and Reimbursement Overview
17. KOL Views on the Post-Traumatic Stress Disorder Market.
18. Post-Traumatic Stress Disorder Market Drivers
19. Post-Traumatic Stress Disorder Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings:
https://www.delveinsight.com/sample-request/post-traumatic-stress-disorder-ptsd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Trending Market Research Reports 2032 | DelveInsight

Technical Due Diligence Firms- https://www.delveinsight.com/consulting/due-diligence-services

Vital Sign Monitors Devices Market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market

Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market

Anastomosis Device Market- https://www.delveinsight.com/report-store/anastomotic-leak-devices-market

Asperger Syndrome Market- https://www.delveinsight.com/report-store/asperger-syndrome-market

B-Cell Maturation Antigen Targeted Therapies Market- https://www.delveinsight.com/report-store/b-cell-maturation-antigen-targeted-therapies-market

UK Healthcare Report- https://www.delveinsight.com/report-store/uk-healthcare-outlook-report

Oncolytic Virus Cancer Therapy Pipeline- https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-pipeline-insight-2021

Shingles Market- https://www.delveinsight.com/report-store/shingles-market

Progressive Supranuclear Palsy Market- https://www.delveinsight.com/report-store/progressive-supranuclear-palsy-market

Tay-Sachs Disease Market- https://www.delveinsight.com/report-store/tay-sachs-disease-market

Shigellosis Market- https://www.delveinsight.com/report-store/shigellosis-market

Gene Therapy In CNS Disorder Market- https://www.delveinsight.com/report-store/gene-therapy-in-cns-disorder-market

Hypertrophic Cardiomyopathy Market- https://www.delveinsight.com/report-store/hypertrophic-cardiomyopathy-market

Varicella Zoster (HHV-3) Infections Market- https://www.delveinsight.com/report-store/varicella-zoster-hhv-3-infections-market

Vasculitis Market- https://www.delveinsight.com/report-store/vasculitis-market

Vascular Imaging Devices Market- https://www.delveinsight.com/report-store/vascular-imaging-market-market

Interbody Cages Market- https://www.delveinsight.com/report-store/interbody-cages-market

Acoustic Neuroma Market- https://www.delveinsight.com/report-store/acoustic-neuroma-market

Meningioma Market- https://www.delveinsight.com/report-store/meningioma-market

Age-related Vision Dysfunction Market- https://www.delveinsight.com/report-store/age-related-vision-dysfunction-market

Thymic Carcinoma Market- https://www.delveinsight.com/report-store/thymic-carcinoma-market

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.